INTRODUCTION
============

To evaluate the risk impact of lifestyle factors and levels of serum components on human health, in the late 1980s we established a large-scale cohort study, the Japan Collaborative Cohort Study for Evaluation of Cancer Risk (JACC Study). During a follow-up period of approximately 20 years, data on deaths from major causes such as stomach cancer, lung cancer, and cardiovascular diseases enabled examination of risk factors. We subsequently published results regarding associations between lifestyle factors and health status in almost 200 original research articles in peer-reviewed English-language journals. Additionally, we are currently developing a website to increase public awareness.^[@r01]^

The enthusiasm of researchers is always important in promoting a cohort study, but enthusiasm is not enough since such work takes many years to bear fruit. A substantial budget is also required. The JACC Study was started after receiving a promise of funds for 10 years; however, after the initial 10 years had passed, it became necessary to apply for small public grants to maintain and follow cohort participants. In addition, administrative mergers of cities, towns, and villages throughout Japan in the year 2000 sometimes caused further difficulties in following subjects in the study area, due to changes in partnerships between local governmental offices and researchers. Moreover, with the retirement of key researchers, it was not always easy to transfer their work to their successors. As a result of these challenges, we decided to terminate follow-up of participants in the JACC Study at the end of 2009.

As a final point of interest, we used population registers in the study area to review the list of survivors. Some subjects were found to be no longer living in the study area, although the overall number of such participants was small. Moreover, a small number of errors in the coding of date of birth and sex were identified during follow-up data collection. Here we describe the final cohort profile obtained upon completion of the JACC Study. Data on cancer incidence have not yet been compiled because of the time lag of the cancer registry system. This process is expected to continue until 2013, at which point incidence information until 2009 will be made available.

METHODS
=======

Study subjects
--------------

Details of the study design and concept have been described elsewhere.^[@r02]--[@r04]^ Briefly, the JACC Study was a multicenter collaborative study in which 24 institutions voluntarily participated. Recruitment of study subjects living in 45 areas was managed by individual investigators whose responsibility was to construct the cohort in that area. Data were collected from 1988 through 1990. However, although most baseline surveys were performed during this 3-year period, some subjects were recruited before and after this period because of the need for a preliminary study in 3 areas and later collaboration in 1 area. Individual informed consent before participation in the study was obtained in 36 of the 45 study areas (written consent in 35 areas and oral consent in 1 area); in the remaining 9 areas, group consent from the area leader was obtained. Participant eligibility was verified by individual investigators, who confirmed that (1) the participant was living within the study area and (2) was aged 40 to 79 years at baseline. In addition, date of birth and sex were further verified using official documents and/or a completed self-administered questionnaire.

Follow-up
---------

As follow-up information, dates and causes of death were annually or biannually confirmed, with the permission of the Director-General of the Prime Minister's Office (Ministry of Public Management, Home Affairs, Post and Telecommunications) and/or the Ministry of Health, Labor and Welfare, Japan. The date of move-out of cohort members from the study area was also annually or biannually verified by the investigator in cooperation with key members of the local governmental office. In 24 of the 45 areas, data on cancer incidence such as date of diagnosis and primary site were also collected through population-based cancer registers or by reviewing the records of local major hospitals. In most areas, follow-up was completed at the end of 2009; however, it was stopped at the end of 1999 in 4 areas, at the end of 2003 in another 4 areas, and at the end of 2008 in 2 areas.

Final data setup: correction of birth date and sex information, identification of decedents and subjects who had moved, and deletion of ineligible participants
---------------------------------------------------------------------------------------------------------------------------------------------------------------

To confirm if study participants had survived and were living in the study area at the end of follow-up, we conducted a systematic review of population registers of cohort members in 17 areas followed until 2009. In the remaining 18 areas followed until 2009, annual or biannual follow-up surveys were routinely performed using population registers; thus, no further reviews were conducted. If data from participants presumed to survive were found to be missing at the end of 2009, attempts were made to obtain information on their mortality status or current location, and relevant information was added to the follow-up data. A few participants were found to have never lived in the study area and were thus excluded from the baseline data.

This review process revealed some errors in coding of date of birth and sex. Moreover, during the merge of follow-up data with baseline identifiable data (name, date of birth, and sex), further errors in date of birth and sex were found. All such errors were corrected.

RESULTS
=======

Of 110 792 participants aged 40 to 79 years at baseline, 207 (0.19%) were found to have never lived in the study area. As a result, 110 585 participants (46 395 men and 64 190 women) were ultimately deemed eligible as subjects for the JACC Study, with 707 136 and 1 025 703 person-years of follow-up for men and women, respectively. Errors in the coding of date of birth and sex were found in 356 (0.32%) and 59 (0.05%) cases, respectively, during routine follow-up and final review. Table [1](#tbl01){ref-type="table"} shows the age and sex distribution of study participants. There were no subjects from the Shikoku region. As compared with the overall distribution of the Japanese population in 1989, our cohort participants were slightly older and included a higher percentage of women.

###### Age distribution of cohort members at baseline by region

                                                  Age at baseline   Total   \%                                                     
  ------- --------------------------------------- ----------------- ------- ------ -------- -------- ------ ------ ------ -------- -------
  Men                                                                                                                              
          Japan general population 1989 (×1000)   5022              4562    3967   3706     3122     2049   1507   1169   25 104    
                                                  20.0              18.2    15.8   14.8     12.4     8.2    6.0    4.7    100.0     
                                                                                                                                   
          JACC Study participants                 5991              5794    6309   7690     8415     5516   4021   2659   46 395   100.0
          \%                                      12.9              12.5    13.6   16.6     18.1     11.9   8.7    5.7    100.0     
                                                                                                                                   
          Hokkaido                                191               182     211    267      284      201    86     43     1465     3.2
          Tohoku                                  809               625     797    1050     1270     894    494    293    6232     13.4
          Kanto                                   1325              1231    1219   1320     1446     1115   707    447    8810     19.0
          Chubu                                   1736              1646    1560   1763     1804     1167   916    691    11 283   24.3
          Kinki                                   960               908     1148   1456     1419     996    651    459    7997     17.2
          Chugoku                                 220               374     452    886      1251     589    770    509    5051     10.9
          Kyushu                                  750               828     922    948      941      554    397    217    5557     12.0
                                                                                                                                   
  Women                                                                                                                            
          Japan general population 1989 (×1000)   4989              4613    4052   3852     3426     2825   2141   1770   27 668    
                                                  18.0              16.7    14.6   13.9     12.4     10.2   7.7    6.4    100.0     
                                                                                                                                   
          JACC Study participants                 7536              7912    9088   10 792   11 102   8589   5548   3623   64 190   100.0
          \%                                      11.7              12.3    14.2   16.8     17.3     13.4   8.6    5.6    100.0     
                                                                                                                                   
          Hokkaido                                310               310     433    436      382      257    93     37     2258     3.5
          Tohoku                                  959               963     1412   1670     1670     1136   604    372    8786     13.7
          Kanto                                   1428              1438    1442   1605     1744     1577   892    542    10 668   16.6
          Chubu                                   1872              1669    1833   1933     2107     1613   1225   882    13 134   20.5
          Kinki                                   1253              1219    1508   1784     1566     1300   876    623    10 129   15.8
          Chugoku                                 300               796     828    1479     2194     1795   1289   844    9525     14.8
          Kyushu                                  1414              1517    1632   1885     1439     911    569    323    9690     15.1

Table [2](#tbl02){ref-type="table"} shows the follow-up results, and Table [3](#tbl03){ref-type="table"} shows the major causes of death up to 2009. These values include the follow-up information (death or move-out from the study area) that was reported in 10 of 17 areas for 516 subjects (0.5%) through a systematic review of population registers of cohort members. Finally, 27 410 deaths (24.8%; 15 401 men, 12 009 women) and 6402 move-outs (5.8%; 2343 men, 4059 women) were identified during the median 18.0-year follow-up. The first cause of death was cancer among men (37.6%) and circulatory disease among women (33.7%), and the second cause of death was circulatory disease (27.8%) and cancer (30.8%), respectively (Table [3](#tbl03){ref-type="table"}). Among those who died of cancer, the first, second, and third leading causes of death were cancer of the lung (23.2%), stomach (18.4%), and liver (10.7%) among men and cancer of the stomach (15.4%), lung (11.2%), liver, and pancreas (9.2% for both) among women. When cancers of the colon and rectum were grouped together, that category was the second leading cause of death (12.7%) among women.

###### Follow-up status until 2009 by sex and age

                                            Age at baseline   Total                                                               
  ----------------------------------------- ----------------- --------- --------- --------- --------- --------- -------- -------- -----------
  Men                                                                                                                              
   No. at baseline                          5991              5794      6309      7690      8415      5516      4021     2659     46 395
   No. of deaths                            394               658       1113      2000      3252      3056      2782     2146     15 401
   %                                        6.6               11.4      17.6      26.0      38.6      55.4      69.2     80.7     33.2
   No. who left study area                  539               377       303       298       292       242       180      112      2343
   %                                        9.0               6.5       4.8       3.9       3.5       4.4       4.5      4.2      5.1
   Person-years                             107 048           102 338   108 465   124 421   123 896   74 267    43 689   23 012   707 136
   Mortality rate (per 1000 person-years)   3.7               6.4       10.3      16.1      26.2      41.1      63.7     93.3     21.8
  Women                                                                                                                            
   No. at baseline                          7536              7912      9088      10 792    11 102    8589      5548     3623     64 190
   No. of deaths                            242               368       637       1218      1982      2544      2632     2386     12 009
   %                                        3.2               4.7       7.0       11.3      17.9      29.6      47.4     65.9     18.7
   No. who left study area                  605               488       479       522       606       592       483      284      4059
   %                                        8.0               6.2       5.3       4.8       5.5       6.9       8.7      7.8      6.3
   Person-years                             134 927           139 091   159 465   182 347   174 721   125 510   71 076   38 566   1 025 703
   Mortality rate (per 1000 person-years)   1.8               2.6       4.0       6.7       11.3      20.3      37.0     61.9     11.7

###### Mortality distribution according to cause of death during entire follow-up period

  Cause of death   Men                                                                                        Women                                                                                                                                                                                                       
  ---------------- ------------------------------------------------------------------------------------------ ------------------------------------------------- ------ ------ ------ ------ ------ ------ -------- ------- ------ ------- ------ ----- ------ ------ ------ ------ ------ -------- ------- ------ ------- ------
  All causes       394                                                                                        658                                               1113   2000   3252   3056   2782   2146   15 401   100.0          242     368    637   1218   1982   2544   2632   2386   12 009   100.0                  
                                                                                                                                                                                                                                                                                                                          
  A00--B99         Certain infectious and parasitic diseases                                                  6                                                 10     18     38     56     62     44     33       267     1.7            4      4     18     31     62     50     43     36       248     2.1            
                                                                                                                                                                                                                                                                                                                          
  C00--D49         Neoplasms                                                                                  160                                               312    542    927    1425   1073   792    561      5792    37.6   100.0   147    182   319    563    740    714    618    414      3697    30.8   100.0   
   C15                                                                                                        Esophagus                                         12     14     28     42     55     38     17       10      216            3.7    0     1      5      3      4      7      8        7       35             0.9
   C16                                                                                                        Stomach                                           32     62     87     176    252    199    151      109     1068           18.4   19    26     33     93     91     127    104      76      569            15.4
   C18                                                                                                        Colon                                             12     14     36     41     67     59     44       35      308            5.3    2     13     29     45     62     65     65       52      333            9.0
   C19--C20                                                                                                   Rectum                                            8      17     26     52     39     30     27       22      221            3.8    9     8      12     18     35     16     26       11      135            3.7
   C22                                                                                                        Liver and intrahepatic bile ducts                 21     46     79     128    167    77     66       37      621            10.7   8     12     29     65     81     77     33       35      340            9.2
   C23                                                                                                        Gall bladder                                      1      5      6      16     17     32     12       12      101            1.7    4     7      11     15     17     28     35       13      130            3.5
   C24                                                                                                        Other and unspecified parts of biliary tract      5      11     11     34     41     42     28       16      188            3.2    3     8      11     22     31     37     37       23      172            4.7
   C25                                                                                                        Pancreas                                          13     20     29     50     78     63     43       42      338            5.8    7     16     26     48     82     66     62       33      340            9.2
   C33--C34                                                                                                   Lung                                              27     50     114    205    364    290    181      114     1345           23.2   18    20     39     54     96     78     70       40      415            11.2
   C50                                                                                                        Breast                                            0      1      0      0      0      0      1        0       2              0.0    28    26     28     37     29     18     17       9       192            5.2
   C53                                                                                                        Cervic uteri                                                                                                                       6     2      10     5      9      5      7        5       49             1.3
   C54                                                                                                        Corpus uteri                                                                                                                       2     2      7      7      9      3      4        2       36             1.0
   C55                                                                                                        Uterus, part unspecified                                                                                                           2     3      1      3      13     9      8        7       46             1.2
   C56                                                                                                        Ovary                                                                                                                              13    8      15     16     22     10     9        5       98             2.7
   C61                                                                                                        Prostate                                          2      4      20     21     68     49     59       56      279            4.8                                                                              
   C64                                                                                                        Kidney                                            0      4      7      12     14     9      12       4       62             1.1    0     0      1      5      3      11     5        1       26             0.7
   C65--C67                                                                                                   Urothelial tract                                  2      7      13     11     40     31     34       17      155            2.7    1     0      6      6      21     14     16       14      78             2.1
   C82--C85                                                                                                   Non-Hodgkin's lymphoma                            0      8      17     29     44     20     15       15      148            2.6    5     6      10     25     23     17     12       7       105            2.8
   C90                                                                                                        Multiple myeloma                                  2      7      4      12     18     12     9        5       69             1.2    4     4      9      12     15     15     11       10      80             2.2
   C92                                                                                                        Myeloid leukemia                                  5      10     11     16     17     7      9        3       78             1.3    1     4      4      12     15     9      8        3       56             1.5
                                                                                                                                                                                                                                                                                                                          
  E00--E89         Endocrine, nutritional and metabolic diseases                                              8                                                 10     17     29     38     35     27     28       192     1.2            2      4     7      10     36     49     48     43       199     1.7            
                                                                                                                                                                                                                                                                                                                          
  G00--G99         Diseases of the nervous system                                                             4                                                 7      17     19     50     39     18     10       164     1.1            1      4     12     23     44     27     29     13       153     1.3            
                                                                                                                                                                                                                                                                                                                          
  I00--I99         Diseases of the circulatory system                                                         86                                                132    252    460    857    908    919    673      4287    27.8           52     70    138    306    585    913    1001   978      4043    33.7           
   I20--I25                                                                                                   Ischemic heart disease                            34     45     69     124    199    204    181      147     1003                  11    8      34     51     105    188    176      185     758             
   I48                                                                                                        Atrial fibrillation and flutter                   0      0      4      10     19     25     24       15      97                    1     0      1      3      16     21     29       26      97              
   I50                                                                                                        Heart failure                                     7      19     26     56     121    151    178      153     711                   8     5      22     44     101    180    200      239     799             
   I60--I69                                                                                                   Cerebrovascular disease                           30     44     113    194    362    389    408      285     1825                  24    43     63     130    256    393    461      407     1777            
   I71                                                                                                        Aortic aneurysm and dissection                    4      4      12     21     44     40     38       15      178                   2     3      2      17     22     29     28       13      116             
                                                                                                                                                                                                                                                                                                                          
  J00--J99         Diseases of the respiratory system                                                         14                                                40     62     219    408    501    550    500      2294    14.9           3      18    23     67     182    281    357    354      1285    10.7           
   J09--J18                                                                                                   Influenza and pneumonia                           6      20     30     115    228    273    327      327     1326                  2     11     15     39     110    173    247      245     842             
   J43                                                                                                        Emphysema                                         0      1      6      19     58     58     64       44      250                   0     0      0      2      2      4      4        4       16              
                                                                                                                                                                                                                                                                                                                          
  K00--K95         Diseases of the digestive system                                                           28                                                35     53     78     82     109    80     46       511     3.3            1      12    13     54     54     106    91     82       413     3.4            
   K74                                                                                                        Fibrosis and cirrhosis of liver                   16     16     27     34     20     13     19       6       151                   1     8      6      23     22     31     19       10      120             
                                                                                                                                                                                                                                                                                                                          
  N00--N99         Diseases of the genitourinary system                                                       2                                                 9      14     33     67     68     67     59       319     2.1            2      3     15     22     51     78     82     81       334     2.8            
   N17--N19                                                                                                   Acute kidney failure and chronic kidney disease   2      7      12     22     50     52     52       53      250                   1     2      12     17     38     50     63       60      243             
                                                                                                                                                                                                                                                                                                                          
  R00--R99         Symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified   4                                                 4      6      7      26     52     99     109      307     2.0            1      1     1      7      26     84     172    234      526     4.4            
   R54                                                                                                        Age-related physical debility                     0      0      0      4      19     37     87       99      246                   0     0      1      2      18     71     150      224     466             
                                                                                                                                                                                                                                                                                                                          
  S00--T88         External causes                                                                            78                                                86     113    150    170    150    126    93       966     6.3            22     57    72     97     143    147    117    73       728     6.1            
                                                                                                                                                                                                                                                                                                                          
                   Others                                                                                     4                                                 13     19     40     73     59     60     34       302     2.0            7      13    19     38     59     95     74     78       383     3.2            

^a^Percentage of deaths per neoplasm.

DISCUSSION
==========

This final profile of the JACC Study Group describes the number of participants and their follow-up status. During the median 18-year follow-up, we found errors in the coding of date of birth and sex data as well as incorrectly registered cases. Accordingly, we would advise future researchers planning a field study to thoroughly check participant eligibility and basic information such as date of birth and sex; this can be performed at least twice, by using a population register and a self-questionnaire.

Although follow-up information was annually or biannually confirmed, 516 subjects who had died or moved out of the study area were not identified during routine follow-up. The use of population registers to verify that subjects are living in the study area is therefore necessary because it enables identification of deceased individuals and those who have moved out of the study area. Furthermore, 356 (0.32%) and 59 (0.05%) cases of incorrect coding of date of birth and sex, respectively, were found during routine follow-up and final review. Miscoding of data can occur by verification only once, and miscoding of date of birth and sex information may cause errors such as merging of the follow-up information of 1 participant with the baseline data of another participant. Thus, careful efforts such as independent double-entry are essential to reduce such miscoding.

The JACC Study is one of the largest cohort studies in Japan. Selected characteristics of study participants were similar to those of the Japanese general population, and thus, the JACC Study can be regarded as representative of the Japanese population, though it should be noted that no subjects were recruited from the Shikoku region. Almost 200 original articles on the risk factors for cancer, cardiovascular disease, and other diseases have been published using the results of the JACC Study. It was not an easy task to establish and maintain such a large collaborative cohort study with a limited budget; the voluntary efforts of the collaborators were essential. Although unexpected errors were found, we believe that the impact of these errors was negligible because the number of ineligible cases and amount of missing data were small relative to the large total study population.

Cohort studies need to continue over a long period if they are to yield fruitful results. Moreover, because all study participants must be followed up carefully and thoroughly, considerable funding is required. The JACC Study received systematic support for the first 10 years, at which point this funding ceased and maintenance and follow-up of cohort participants was accomplished by means of smaller grants. The retirements of principal researchers and city mergers throughout Japan made it difficult to continue follow-up. Thus, we decided to terminate the follow-up of participants in the JACC Study at the end of 2009. Our experience indicates that the development and maintenance of an appropriate long-term management system is essential when launching a cohort study and that adequate and steady support from funding bodies is also important.
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